Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic Acid vs Tranexamic Acid Plus Topical Bacitracin in Lumbar TLIF Surgery
ChiCTR2500114028Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2025
- Modality
- Small Molecules, Antimicrobial Peptides → Native Peptides → Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tranexamic acid and bacitracin in lumbosacral disc disease, Herniated Lumbar Disk, lumbar pseudarthrosis and 1 more (3 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Total blood loss. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
tranexamic acidbacitracin
03
Conditions
lumbosacral disc diseaseHerniated Lumbar Disklumbar pseudarthrosislumbar spondylolisthesis
Beyond the preview
Go deeper on ChiCTR2500114028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114028.